Professor Anna Norhammar

Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

Member of:

Cardiologist in Sweden with interest in diabetes, prediabetes and cardiovascular complications as well as in lifestyle and oral health. Also concerned about how diabetes and prediabetes affects cardiovascular health in women. Experiences from RCT, registries, R-RCT and case- control studies.(DIGAMI, GAMI, Parokrank, SMARTEST, MIMET, Swedeheart). Professor of Cardiology at Karolinska Institutet. Experienced in echocardiography and non-invasiva diagnostics. Member of the Swedish Society of Cardiology steering group, and president 2024-2026.

Presentations Articles Podcasts

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

Event: ESC Congress 2019

Topic: Diabetes and the Heart

Session: SGLT2 inhibitors and cardiovascular outcomes

Access

State of the Art in antidiabetic treatment to prevent CVD

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: The right glucose-lowering drugs for the right patient

Access

Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

Event: ESC Congress 2017

Topic: Heart failure, other

Session: Late-Breaking Science in Heart Failure

Access

Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Population studies / Epidemiology

Session: Clinical Forum - Sat. 29 April 08:30 - Tues. 02 May at 12:30

Access

Periodontal disease - A potential risk factor for myocardial infarction in younger women

Event: ESC Congress 2016

Topic: Epidemiology, lipids

Session: Cardiovascular risk in populations

Access

ESC 365 is supported by

Explore sponsored resources

Professor Anna Norhammar

Biography

Contributor content

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

State of the Art in antidiabetic treatment to prevent CVD

Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

Periodontal disease - A potential risk factor for myocardial infarction in younger women

ESC 365 is supported by

Professor Anna Norhammar Follow

Biography

Contributor content

SGLT2 inhibitors and atherosclerosis-related outcomes: the good and the bad

State of the Art in antidiabetic treatment to prevent CVD

Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

Dapagliflozin is associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all-cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic

Periodontal disease - A potential risk factor for myocardial infarction in younger women

ESC 365 is supported by

Professor Anna Norhammar